“…Considering the important role that HATs and HDACs play in gene regulation, it has not come as a surprise that alterations in HAT and HDAC activity have been correlated with human diseases. For example, chromosomal translocations involving the monocytic leukemia zinc finger protein (MOZ) and p300/CBP HATs are associated with acute myeloid leukemias and p300/CBP have properties of tumor suppressor proteins (Muraoka et al, 1996;Giles et al, 1998;Chaffanet et al, 2000;Timmermann, 2001). In addition, class I/II HDACs have emerged as attractive targets for cancer therapy, as HDAC inhibitors have been found to have potent and specific anticancer activities in preclinical studies (Kelly et al, 2002(Kelly et al, , 2003Marks and Jiang, 2005;Bolden et al, 2006).…”